^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CDKN2A promoter methylation

i
Other names: CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Entrez ID:
Related biomarkers:
2ms
CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine. (PubMed, Mol Biol Rep)
Our findings demonstrate that CDKN2A downregulation in glioblastoma cells is associated with decreased cell viability, enhanced drug resistance, increased self-renewal capacity, and altered expression of pluripotency markers. The observed CDKN2A expression changes are mediated by promoter methylation. These results highlight the potential role of CDKN2A as a therapeutic target and prognostic marker in glioblastoma.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CDKN2A overexpression • CDKN2A promoter methylation • CDKN2A expression
|
carmustine
almost2years
Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. (PubMed, Mol Carcinog)
Importantly, PI3K inhibitor sensitivity was not necessarily a cancer cell-intrinsic property, and the tumor microenvironment impacts therapeutic response and supports CSCs. Additionally, combined inhibition of EGFR with PI3K inhibitor diminished EGFR activation induced by PI3K inhibitor and potently inhibited cancer cell proliferation and CSC maintenance.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor)
|
TP53 mutation • CDKN2A promoter methylation
almost2years
Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus. (PubMed, Clin Epigenetics)
Our study further enlightens the molecular background of BE and EAC. To the best of our knowledge, this is one of the largest studies addressing a targeted analysis of genetic and epigenetic modifications simultaneously across a combined series of non-dysplastic BE and EAC samples.
Journal
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
|
TP53 mutation • CDKN2A promoter methylation
over2years
Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. (PubMed, J Pathol)
In summary, mucosal, conjunctival, and cutaneous melanomas show a surprisingly similar global DNA methylation profile and identification of the site of origin by DNA methylation testing is likely not feasible. Still, our study demonstrates tumor location-dependent differences of promoter methylation frequencies in specific cancer related genes together with tumor site-specific enrichment for specific chromosomal changes and genetic mutations.
Clinical • Journal • Epigenetic controller
|
PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
PTEN expression • CDKN2A promoter methylation • TERT amplification
almost3years
[VIRTUAL] Molecular Features Associated with Over 36- and 120-Month Survival in Three Large Cohorts of Glioblastoma Patients (AANP 2021)
These data agree with our re-analysis of 2,328 previously published cases (LTS n=465) (Richardson et al., 2020). While there is no definitive molecular signature that guarantees long-term survival in glioblastoma patients in this dataset, these results suggest a constellation of clinical and molecular features that may help guide clinical decision making and predict which patients have the best odds of long-term survival.
Clinical
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
CDKN2A deletion • MGMT promoter methylation • CDKN2A promoter methylation
almost4years
GSTs polymorphisms are associated with epigenetic silencing of CDKN2A gene in esophageal squamous cell carcinoma. (PubMed, Environ Sci Pollut Res Int)
There was significant association between methylated states of CDKN2A and high concentrations of 1-OHP in urine (p < 0.01). We identified significant association between polymorphism of GSTs genes and epigenetic silencing of tumor suppressor gene CDKN2A in esophageal squamous cell carcinoma.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1)
|
CDKN2A promoter methylation
almost4years
[VIRTUAL] Recognition of aberrant promoter methylation for early diagnosis of lung cancer patients (ERS 2020)
In conclusion our results suggest that the sputum is a useful noninvasive tool to identify the epigenetic alteration such as gene promoter methylation. Further, as per the findings of the present study we concluded that the potential of MSP based molecular characterization may be a useful molecular technique for early detection of lung cancer.
Clinical
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDH1 (Cadherin 1)
|
CDKN2A promoter methylation